Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website

Intra Cellular Therapies

Intra Cellular Therapies reported $79.59M in Current Liabilities for its fiscal quarter ending in March of 2023.

Current Liabilities Change
Acadia Pharmaceuticals ACAD:US USD 224.3M 98.67M
Biogen BIIB:US USD 3.01B 257.9M
Cytokinetics CYTK:US USD 75.22M 9.4M
Esperion Therapeutics ESPR:US USD 95.49M 3.18M
Gilead Sciences GILD:US USD 10.53B 709M
Halozyme Therapeutics HALO:US USD 91.92M 38.87M
Intra Cellular Therapies ITCI:US USD 79.59M 3.65M
J&J JNJ:US USD 60.37B 4.57B
Marinus Pharmaceuticals MRNS:US USD 21.51M 3.5M
Minerva Neurosciences NERV:US USD 2.5M 1.12M
Nektar Therapeutics NKTR:US USD 59.88M 8.32M
Neurocrine Biosciences NBIX:US USD 374.1M 163.6M
Novartis NVS:US USD 30.55B 1.89B
Prothena PRTA:US USD 48.88M 1.26M
RedHill Biopharma RDHL:US USD 197.45M 3.92M
Supernus Pharmaceuticals SUPN:US USD 731.54M 43.59M
United Therapeutics UTHR:US USD 324.6M 18.6M
Vanda Pharmaceuticals VNDA:US USD 93.79M 2.36M